SURVIVAL OF DLBCL PATIENTS IN FIRST REMISSION RELATIVE TO A MATCHED BACKGROUND POPULATION
(Abstract release date: 05/19/16)
EHA Library. Hjort Jakobsen L. 06/11/16; 135234; S478
Mr. Lasse Hjort Jakobsen
Contributions
Contributions
Abstract
Abstract: S478
Type: Oral Presentation
Presentation during EHA21: On Saturday, June 11, 2016 from 16:15 - 16:30
Location: Hall A1
Background
Communicating prognosis in a plain language to patients with diffuse large B-cell lymphoma (DLBCL) and their relatives can be challenging. Survival of DLBCL patients relative to a matched background population (MBP) represents a relevant measure of prognosis.
Aims
The purpose of this study was to investigate the post-treatment survival of DLBCL patients in CR/CRu relative to an MBP and to examine the duration of CR/CRu needed to obtain similar survival to the MBP.
Methods
This retrospective study utilized the nationwide Danish Lymphoma Registry (LYFO). We included patients fulfilling the following criteria: a) newly diagnosed DLBCL in the period 2003-2011, b) ≥15yrs of age at diagnosis, and c) achieving CR or CRu after 1st line R-CHOP(-like) therapy. Survival curves were generated using the Kaplan-Meier method and survival of the MBP was established from lifetime tables.
Results
In total, 1632 Danish DLBCL patients met the inclusion criteria and the baseline characteristics were similar to that seen in previous studies. The median follow-up from diagnosis was 85 months. The 5-year OS of the MBP was superior to that of the DLBCL patients (88% vs. 78%, p<0.001). In analyses restricted to patients in continuous CR/CRu for >2 and 5 years, the OS of DLBCL patients remained inferior to that of an MBP (p<0.001 for 2 years; p<0.001 for 5 years). Age-stratified analyses (<50yrs vs. ≥50yrs) showed, the OS of patients <50yrs became identical to that of an MBP after only two years in continuous CR/CRu (p=0.90). For DLBCL patients ≥50yrs, however, the OS remained inferior past 5 years of continuous CR/CRu. The OS of DLBCL patients ≥50 years were still inferior after censoring patients with relapses (p<0.001).
Conclusion
The OS of DLBCL patients in CR/CRu after R-CHOP(-like) therapy was inferior to that of an MBP, but the differences were gradually reduced for patients with durable remission. Interestingly, the OS of young DLBCL patients (<50yrs) quickly became identical to that of an MBP. However this was not the case for patients ≥50yrs, even after excluding those with relapse. This suggests that the residual life expectancy of this subgroup of patients may be reduced due to late toxicities or other causes not directly related to DLBCL.
Session topic: Diffuse large B-cell lymphoma
Keyword(s): Diffuse large B cell lymphoma, Survival
Type: Oral Presentation
Presentation during EHA21: On Saturday, June 11, 2016 from 16:15 - 16:30
Location: Hall A1
Background
Communicating prognosis in a plain language to patients with diffuse large B-cell lymphoma (DLBCL) and their relatives can be challenging. Survival of DLBCL patients relative to a matched background population (MBP) represents a relevant measure of prognosis.
Aims
The purpose of this study was to investigate the post-treatment survival of DLBCL patients in CR/CRu relative to an MBP and to examine the duration of CR/CRu needed to obtain similar survival to the MBP.
Methods
This retrospective study utilized the nationwide Danish Lymphoma Registry (LYFO). We included patients fulfilling the following criteria: a) newly diagnosed DLBCL in the period 2003-2011, b) ≥15yrs of age at diagnosis, and c) achieving CR or CRu after 1st line R-CHOP(-like) therapy. Survival curves were generated using the Kaplan-Meier method and survival of the MBP was established from lifetime tables.
Results
In total, 1632 Danish DLBCL patients met the inclusion criteria and the baseline characteristics were similar to that seen in previous studies. The median follow-up from diagnosis was 85 months. The 5-year OS of the MBP was superior to that of the DLBCL patients (88% vs. 78%, p<0.001). In analyses restricted to patients in continuous CR/CRu for >2 and 5 years, the OS of DLBCL patients remained inferior to that of an MBP (p<0.001 for 2 years; p<0.001 for 5 years). Age-stratified analyses (<50yrs vs. ≥50yrs) showed, the OS of patients <50yrs became identical to that of an MBP after only two years in continuous CR/CRu (p=0.90). For DLBCL patients ≥50yrs, however, the OS remained inferior past 5 years of continuous CR/CRu. The OS of DLBCL patients ≥50 years were still inferior after censoring patients with relapses (p<0.001).
Conclusion
The OS of DLBCL patients in CR/CRu after R-CHOP(-like) therapy was inferior to that of an MBP, but the differences were gradually reduced for patients with durable remission. Interestingly, the OS of young DLBCL patients (<50yrs) quickly became identical to that of an MBP. However this was not the case for patients ≥50yrs, even after excluding those with relapse. This suggests that the residual life expectancy of this subgroup of patients may be reduced due to late toxicities or other causes not directly related to DLBCL.
Session topic: Diffuse large B-cell lymphoma
Keyword(s): Diffuse large B cell lymphoma, Survival
Abstract: S478
Type: Oral Presentation
Presentation during EHA21: On Saturday, June 11, 2016 from 16:15 - 16:30
Location: Hall A1
Background
Communicating prognosis in a plain language to patients with diffuse large B-cell lymphoma (DLBCL) and their relatives can be challenging. Survival of DLBCL patients relative to a matched background population (MBP) represents a relevant measure of prognosis.
Aims
The purpose of this study was to investigate the post-treatment survival of DLBCL patients in CR/CRu relative to an MBP and to examine the duration of CR/CRu needed to obtain similar survival to the MBP.
Methods
This retrospective study utilized the nationwide Danish Lymphoma Registry (LYFO). We included patients fulfilling the following criteria: a) newly diagnosed DLBCL in the period 2003-2011, b) ≥15yrs of age at diagnosis, and c) achieving CR or CRu after 1st line R-CHOP(-like) therapy. Survival curves were generated using the Kaplan-Meier method and survival of the MBP was established from lifetime tables.
Results
In total, 1632 Danish DLBCL patients met the inclusion criteria and the baseline characteristics were similar to that seen in previous studies. The median follow-up from diagnosis was 85 months. The 5-year OS of the MBP was superior to that of the DLBCL patients (88% vs. 78%, p<0.001). In analyses restricted to patients in continuous CR/CRu for >2 and 5 years, the OS of DLBCL patients remained inferior to that of an MBP (p<0.001 for 2 years; p<0.001 for 5 years). Age-stratified analyses (<50yrs vs. ≥50yrs) showed, the OS of patients <50yrs became identical to that of an MBP after only two years in continuous CR/CRu (p=0.90). For DLBCL patients ≥50yrs, however, the OS remained inferior past 5 years of continuous CR/CRu. The OS of DLBCL patients ≥50 years were still inferior after censoring patients with relapses (p<0.001).
Conclusion
The OS of DLBCL patients in CR/CRu after R-CHOP(-like) therapy was inferior to that of an MBP, but the differences were gradually reduced for patients with durable remission. Interestingly, the OS of young DLBCL patients (<50yrs) quickly became identical to that of an MBP. However this was not the case for patients ≥50yrs, even after excluding those with relapse. This suggests that the residual life expectancy of this subgroup of patients may be reduced due to late toxicities or other causes not directly related to DLBCL.
Session topic: Diffuse large B-cell lymphoma
Keyword(s): Diffuse large B cell lymphoma, Survival
Type: Oral Presentation
Presentation during EHA21: On Saturday, June 11, 2016 from 16:15 - 16:30
Location: Hall A1
Background
Communicating prognosis in a plain language to patients with diffuse large B-cell lymphoma (DLBCL) and their relatives can be challenging. Survival of DLBCL patients relative to a matched background population (MBP) represents a relevant measure of prognosis.
Aims
The purpose of this study was to investigate the post-treatment survival of DLBCL patients in CR/CRu relative to an MBP and to examine the duration of CR/CRu needed to obtain similar survival to the MBP.
Methods
This retrospective study utilized the nationwide Danish Lymphoma Registry (LYFO). We included patients fulfilling the following criteria: a) newly diagnosed DLBCL in the period 2003-2011, b) ≥15yrs of age at diagnosis, and c) achieving CR or CRu after 1st line R-CHOP(-like) therapy. Survival curves were generated using the Kaplan-Meier method and survival of the MBP was established from lifetime tables.
Results
In total, 1632 Danish DLBCL patients met the inclusion criteria and the baseline characteristics were similar to that seen in previous studies. The median follow-up from diagnosis was 85 months. The 5-year OS of the MBP was superior to that of the DLBCL patients (88% vs. 78%, p<0.001). In analyses restricted to patients in continuous CR/CRu for >2 and 5 years, the OS of DLBCL patients remained inferior to that of an MBP (p<0.001 for 2 years; p<0.001 for 5 years). Age-stratified analyses (<50yrs vs. ≥50yrs) showed, the OS of patients <50yrs became identical to that of an MBP after only two years in continuous CR/CRu (p=0.90). For DLBCL patients ≥50yrs, however, the OS remained inferior past 5 years of continuous CR/CRu. The OS of DLBCL patients ≥50 years were still inferior after censoring patients with relapses (p<0.001).
Conclusion
The OS of DLBCL patients in CR/CRu after R-CHOP(-like) therapy was inferior to that of an MBP, but the differences were gradually reduced for patients with durable remission. Interestingly, the OS of young DLBCL patients (<50yrs) quickly became identical to that of an MBP. However this was not the case for patients ≥50yrs, even after excluding those with relapse. This suggests that the residual life expectancy of this subgroup of patients may be reduced due to late toxicities or other causes not directly related to DLBCL.
Session topic: Diffuse large B-cell lymphoma
Keyword(s): Diffuse large B cell lymphoma, Survival
{{ help_message }}
{{filter}}